Salix shares fall as company preps investors for likely FDA rejection of IBS drug
25 February 2011
Donna Young
Please Login to read the full article.
25 February 2011
Donna Young
donna.young@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- FDA reviewers question proposed study design for Salix's Xifaxan in IBS
- US Capitol Capsule: Hope not enough for Avastin in MBC; Hamburg explains withdrawal
- Salix issues $600 million in cheap new convertible debt
- US FDA says needs 3 months more to decide fate of Salix's crofelemer
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
